Interestingly, the upfront administration of TKIs and IFN-α, followed by low-dose IFN-α maintenance, enabled a high rate of imatinib discontinuation in CML patients in major molecular response (MMR) [6]. Here, IFNA1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.